Natera (NTRA) Expected to Announce Earnings on Thursday

Key Points

• Natera is expected to report Q3 2026 results after the market closes on November 5. Analysts forecast a loss of $0.2812 per share and revenue of approximately $707.54 million.
• The company’s previous quarter exceeded expectations, with revenue rising 37.7% year over year to $752.75 million and an EPS loss of $0.47 versus the $0.49 consensus estimate.
• Investor sentiment remains broadly positive: analysts have a “Moderate Buy” consensus and an average price target of $394.31, while Natera shares recently traded near their 12-month high at $424.42.

Natera (NASDAQ:NTRA - Get Free Report) is projected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Natera to post earnings of ($0.2812) per share and revenue of $707.54 million for the quarter. Individuals can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The business's quarterly revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.74) EPS. On average, analysts expect Natera to post ($1.14) EPS for the current fiscal year and ($0.10) EPS for the next fiscal year.

Natera Trading Up 3.3%

Shares of NTRA opened at $424.42 on Thursday. The company's 50 day simple moving average is $373.05 and its 200-day simple moving average is $264.53. The firm has a market cap of $61.18 billion, a PE ratio of -312.07 and a beta of 1.50. Natera has a 12-month low of $181.00 and a 12-month high of $437.41.

Analyst Ratings Changes

A number of brokerages recently commented on NTRA. Piper Sandler increased their price objective on shares of Natera from $249.00 to $363.50 and gave the company an "overweight" rating in a research note on Wednesday, August 12th. Citigroup increased their price target on shares of Natera from $365.00 to $480.00 and gave the stock a "buy" rating in a research note on Tuesday, October 6th. Wells Fargo & Company upped their price objective on Natera from $220.00 to $284.00 and gave the stock an "equal weight" rating in a report on Friday, August 7th. Roth Capital assumed coverage on shares of Natera in a research report on Thursday, October 22nd. They set a "buy" rating and a $475.00 target price for the company. Finally, BTIG Research increased their target price on Natera from $320.00 to $430.00 and gave the company a "buy" rating in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and an average price target of $394.31.

Insider Buying and Selling

In other news, insider Solomon Moshkevich sold 15,160 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total value of $4,955,652.40. Following the completion of the sale, the insider directly owned 110,859 shares in the company, valued at approximately $36,238,698.51. The trade was a 12.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,076 shares of Natera stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total value of $819,415.64. Following the completion of the transaction, the chief executive officer directly owned 99,897 shares in the company, valued at approximately $26,611,561.83. This represents a 2.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 38,224 shares of company stock valued at $12,347,229 in the last three months. 5.05% of the stock is currently owned by corporate insiders.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.